[go: up one dir, main page]

PE20141688A1 - Combinacion farmaceutica antineuritica y composiciones - Google Patents

Combinacion farmaceutica antineuritica y composiciones

Info

Publication number
PE20141688A1
PE20141688A1 PE2014000973A PE2014000973A PE20141688A1 PE 20141688 A1 PE20141688 A1 PE 20141688A1 PE 2014000973 A PE2014000973 A PE 2014000973A PE 2014000973 A PE2014000973 A PE 2014000973A PE 20141688 A1 PE20141688 A1 PE 20141688A1
Authority
PE
Peru
Prior art keywords
antineuritic
compositions
pharmaceutical combination
vitamin
hydroxocobalamine
Prior art date
Application number
PE2014000973A
Other languages
English (en)
Inventor
Arroyo Hector Senosiain
Paniagua Maria Angelica Arzola
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48611941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141688(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of PE20141688A1 publication Critical patent/PE20141688A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN ANTIEPILEPTICO TAL COMO PREGABALINA EN UNA CANTIDAD DE 5MG A 600MG, U OXCARBAZEPINA EN UNA CANTIDAD DE 100MG A 2500MG; Y B) VITAMINAS SELECCIONADAS DE i) VITAMINA B12 TAL COMO CIANOCOBALAMINA O HIDROXOCOBALAMINA EN UNA CANTIDAD DE 50mcg A 1000mcg, O ii) VITAMINA B1 Y B12, DONDE LA VITAMINA B1 ES CLORHIDRATO O MONONITRATO DE TIAMINA EN UNA CANTIDAD DE 15MG A 750MG. DICHA COMPOSICION SE ENCUENTRA EN FORMA DE SUSPENSION, COMPRIMIDO, TABLETA, ENTRE OTROS, Y ES UTIL PARA EL TRATAMIENTO DEL DOLOR MODERADO A SEVERO Y NEURALGIAS
PE2014000973A 2011-12-16 2012-12-14 Combinacion farmaceutica antineuritica y composiciones PE20141688A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011014042A MX336979B (es) 2011-12-16 2011-12-16 Combinacion farmaceutica antineuritica y composiciones.

Publications (1)

Publication Number Publication Date
PE20141688A1 true PE20141688A1 (es) 2014-12-03

Family

ID=48611941

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000973A PE20141688A1 (es) 2011-12-16 2012-12-14 Combinacion farmaceutica antineuritica y composiciones

Country Status (14)

Country Link
US (1) US20140323428A1 (es)
BR (1) BR112014014774A2 (es)
CA (1) CA2859487C (es)
CL (1) CL2014001581A1 (es)
CO (1) CO6990712A2 (es)
CR (1) CR20140283A (es)
DO (1) DOP2014000134A (es)
ES (1) ES2525952B1 (es)
GT (1) GT201400115A (es)
MX (1) MX336979B (es)
NI (1) NI201400058A (es)
PE (1) PE20141688A1 (es)
PL (1) PL231163B1 (es)
WO (1) WO2013088410A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826470B1 (en) * 2013-07-19 2017-09-06 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of pregabalin
MX2014008336A (es) 2014-07-07 2016-01-07 Pptm Internat S A R L Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.
PE20251233A1 (es) 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V Tableta multiactivos en el tratamiento y control de dolor severo cronico y metodo de preparacion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065308A2 (en) * 2003-12-29 2005-07-21 Jason Mcdevitt Compositions and methods to treat recurrent medical conditions
CA2701838A1 (en) * 2007-10-09 2009-04-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
US8394759B2 (en) * 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes

Also Published As

Publication number Publication date
GT201400115A (es) 2017-07-27
ES2525952B1 (es) 2015-10-05
PL231163B1 (pl) 2019-01-31
US20140323428A1 (en) 2014-10-30
PL409542A1 (pl) 2015-07-20
CR20140283A (es) 2015-03-11
WO2013088410A1 (es) 2013-06-20
CA2859487C (en) 2016-11-15
BR112014014774A2 (pt) 2017-06-13
MX2011014042A (es) 2013-06-17
NI201400058A (es) 2014-12-22
CO6990712A2 (es) 2014-07-10
ES2525952A1 (es) 2015-01-02
CL2014001581A1 (es) 2014-09-26
CA2859487A1 (en) 2013-06-20
DOP2014000134A (es) 2014-07-31
MX336979B (es) 2016-02-09

Similar Documents

Publication Publication Date Title
EA201400173A1 (ru) Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
CL2019000571A1 (es) Formulaciones de carbamato de (r) -2-amino-3-fenilpropilo.
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
PE20150092A1 (es) Composiciones farmaceuticas que contienen fumarato de dimetilo
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
GT201400111A (es) Triazolopiridinas sustituidas
CL2011001969A1 (es) Forma de dosificación oral en cápsula que comprende 0,1-3% de pomalidomida y 90-99% de un ligante o relleno, el cual es una mezcla de almidón y manitol en razón 1:1 a 1:1,5; y su uso para tratar o prevenir o manejar cáncer, dolor, un desorden del snc, entre otras.
NI201400032A (es) Piridopirazinas anticancerígenas via la
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
PE20140978A1 (es) Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla
MY167918A (en) Composition for use in the sublingual delivery of medicaments to humans
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
GT201200348A (es) Composiciones farmacèuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona
GT201400261A (es) Solicitud pct face nacional novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
BR112015011430A2 (pt) composição para liberação imediata e prolongada
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
IN2014DN01619A (es)
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.

Legal Events

Date Code Title Description
FG Grant, registration